CVS Health stock: Planned 2028 split follows stronger Q3 outlook

Published on 11/10/2026 at 15:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock traded at 76.78 euros on Tuesday afternoon. The company plans to create two public healthcare businesses after stronger third-quarter results.

What changes for investors

CVS Health plans to separate its healthcare solutions and retail pharmacy operations in the first half of 2028.
Third-quarter revenue rose 5.4 percent, while adjusted earnings per share increased to 2.09 US dollars.
Management raised its full-year 2026 adjusted earnings-per-share guidance to at least 8.20 US dollars.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health announced on Wednesday, November 4, that it intends to separate into two independent publicly traded companies, with completion targeted for the first half of 2028. The planned transaction follows stronger third-quarter results and a higher full-year outlook, according to the CVS Health announcement.

Two focused healthcare companies

The healthcare solutions company would include Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. The second company, CVS Pharmacy, would comprise approximately 9,000 retail pharmacies, mail pharmacy services, MinuteClinic, virtual care and Health100.

CVS Health shareholders would own shares in both companies after the separation. The transaction is intended to be tax-free for CVS Health and its shareholders for US federal income tax purposes, subject to customary conditions including final board approval, an effective Form 10 registration statement and tax confirmation.

Stronger quarter lifts outlook

For the quarter ended September 30, CVS Health reported revenue of 108.4 billion US dollars, up 5.4 percent from a year earlier. GAAP diluted earnings per share were 1.68 US dollars, while adjusted earnings per share reached 2.09 US dollars, compared with 1.60 US dollars a year earlier.

The company raised its full-year 2026 adjusted earnings-per-share guidance to at least 8.20 US dollars from a previous range of 7.90 to 8.10 US dollars. It also lifted its cash-flow-from-operations outlook to at least 15.5 billion US dollars. The company said the prior-year GAAP comparison was affected by a 5.7 billion US dollar goodwill impairment charge.

Share price and investor focus

CVS Health stock traded at 76.78 euros on Lang & Schwarz at 15:32 CET on Tuesday, November 10, 2026. Since the November 5 report, the quote has risen from 73.62 euros to 76.78 euros, a 4.29 percent increase. This period comparison is separate from the daily Xetra comparison.

The planned separation gives investors a longer-term structural milestone to monitor, while the raised earnings outlook provides the nearer-term operating benchmark. Execution risks include regulatory approvals, transaction costs and the allocation of assets and liabilities between the future companies.